Amylyx Pharmaceuticals, Inc. (AMLX)
Data as of , from SEC Form 4 filings.
See up to 3 months of AMLX. The 7-day demo opens the 1M and 3M ranges and puts AMLX on your watchlist.
Start 7-day demoLatest AMLX insider trades
About Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
- CAMBRIDGE, MA
- 136
- 2022
- XNAS
AMLX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 11 | 121,302 | $3.78M |
| Grant or award | 5 | 186,976 | |
| Option exercise | 4 | 100,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AMLX insider transactions (Form 4)
4456 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| George M. Milne Jr. - Director | Open-market sale | Common Stock | 30,000 | $27.70 footnote F2 | $831K | |
| ||||||
| Open-market sale | Common Stock | 7,947 | $32.21 footnote F2 | $256K | ||
| Open-market sale | Common Stock | 2,081 | $33.09 footnote F3 | $69K | ||
| ||||||
| James M. Frates - Officer | Open-market sale | Common Stock | 9,768 | $32.27 footnote F2 | $315K | |
| James M. Frates - Officer | Open-market sale | Common Stock | 1,042 | $33.23 footnote F3 | $35K | |
| ||||||
| Open-market sale | Common Stock | 9,525 | $32.46 footnote F2 | $309K | ||
| Open-market sale | Common Stock | 11 | $33.34 | $367 | ||
| ||||||
| Justin B. Klee - Officer | Open-market sale | Common Stock | 29,025 | $32.13 footnote F2 | $933K | |
| Justin B. Klee - Officer | Open-market sale | Common Stock | 1,439 | $33.16 footnote F3 | $48K | |
| ||||||
| Open-market sale | Common Stock | 29,545 | $32.16 footnote F2 | $950K | ||
| Open-market sale | Common Stock | 919 | $33.15 footnote F3 | $30K | ||
| ||||||
| Karen Firestone - Director | Option exercise | Common Stock | 25,000 | $1.76 | $44K | |
| Karen Firestone - Director | Option exercise | Common Stock | 25,000 | $5.05 | $126K | |
| Karen Firestone - Director | Option exercise | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Karen Firestone - Director | Option exercise | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| James M. Frates - Officer | Grant or award | Common Stock | 22,807 footnote F1 | $0.00 | - | |
| ||||||
| Justin B. Klee - Officer | Grant or award | Common Stock | 60,039 footnote F1 | $0.00 | - | |
| ||||||
| Grant or award | Common Stock | 21,284 footnote F1 | $0.00 | - | ||
| ||||||
| Grant or award | Common Stock | 22,807 footnote F1 | $0.00 | - | ||
| ||||||
| Grant or award | Common Stock | 60,039 footnote F1 | $0.00 | - | ||
| ||||||
| Open-market sale | Common Stock | 15,000 | $18.32 footnote F2 | $275K | ||
| Open-market sale | Common Stock | 15,000 | $17.61 footnote F3 | $264K | ||
| ||||||
| Bernhardt G. Zeiher | Grant or award | Stock Option (right to buy) | 24,372 | $0.00 | - | |
| Karen Firestone | Grant or award | Stock Option (right to buy) | 24,372 | $0.00 | - | |
| Daphne Quimi | Grant or award | Stock Option (right to buy) | 24,372 | $0.00 | - | |
| George M. Milne Jr. | Grant or award | Stock Option (right to buy) | 24,372 | $0.00 | - | |
| Grant or award | Stock Option (right to buy) | 24,372 | $0.00 | - | ||
| Karen Firestone | Open-market purchase | Common Stock | 3,800 | $13.51 | $51K | |
| Grant or award | Common Stock | 248,865 footnote F1 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 373,295 | $0.00 | - | ||
| ||||||
| Grant or award | Stock Option (Right to Buy) | 111,990 | $0.00 | - | ||
| Grant or award | Common Stock | 74,660 footnote F1 | $0.00 | - | ||
| ||||||
| James M. Frates - Officer | Grant or award | Common Stock | 95,990 footnote F1 | $0.00 | - | |
| James M. Frates - Officer | Grant or award | Stock Option (right to buy) | 143,985 | $0.00 | - | |
| ||||||
| Justin B. Klee - Officer | Grant or award | Common Stock | 248,865 footnote F1 | $0.00 | - | |
| Justin B. Klee - Officer | Grant or award | Stock Option (Right to Buy) | 373,295 | $0.00 | - | |
| ||||||
| Grant or award | Common Stock | 95,990 footnote F1 | $0.00 | - | ||
| Grant or award | Stock Option (Right to Buy) | 143,985 | $0.00 | - | ||
| ||||||
| Justin B. Klee - Officer | Open-market sale | Common Stock | 29,282 footnote F1 | $14.47 footnote F2 | $424K | |
| ||||||
| Open-market sale | Common Stock | 29,282 footnote F1 | $14.48 footnote F2 | $424K | ||
| ||||||
| Open-market sale | Common Stock | 6,461 footnote F1 | $14.58 footnote F2 | $94K | ||
| ||||||
| James M. Frates - Officer | Open-market sale | Common Stock | 7,909 footnote F1 | $14.52 footnote F2 | $115K | |
| ||||||
| Open-market sale | Common Stock | 6,844 footnote F1 | $14.52 footnote F2 | $99K | ||
| ||||||
| Open-market sale | Common Stock | 3,419 | $14.14 footnote F2 | $48K | ||
| ||||||
Recent AMLX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| GEORGE MILNE | Director | 100,000 | $2.78M | View on EDGAR | |
| Bedrosian Camille L | Officer | 10,028 |
AMLX insider trading FAQ
What is the latest insider trade for AMLX?
Amylyx Pharmaceuticals, Inc. (AMLX) had 12 insider filings in the last 90 days, with the most recent on 2026-10-07. The full record for AMLX runs to 56 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AMLX stock?
No insider purchases of AMLX were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling AMLX stock?
11 insider sales of AMLX were filed in the last 90 days, totaling $3.78M.
Where can I see AMLX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AMLX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - George M. Milne Jr. view on EDGAR
- - Camille L. Bedrosian view on EDGAR
- - James M. Frates view on EDGAR
- - Gina Mazzariello view on EDGAR
- - Justin B. Klee view on EDGAR
- - Joshua B. Cohen view on EDGAR
- - Karen Firestone view on EDGAR
- - James M. Frates view on EDGAR
- - Justin B. Klee view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where AMLX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AMLX with a 7-day demo
- AMLX on your watchlist
- Every AMLX Form 4 filing on record
- Up to 3 months of AMLX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive